YM encouraged by nimotuzumab results

YM BioSciences (AMEX:YMI; TSX:YM) has released results at the ASCO conference from a randomized Phase 2 gastric cancer study of its nimotuzumab drug conducted by its licensees, Daiichi Sankyo in Japan and Kuhnil Pharma in Korea. “The overall findings of the study are positive and support the promise of nimotuzumab in this important global cancer [...]

Canadians’ data heading to ASCO

Versant Partners analyst Doug Loe has compiled a list of six biotech companies that will have data presented at the American Society of Clinical Oncology meeting on June 4 to 8.  He expects: · AEterna Zentaris (NASDAQ:AEZS; TSX:AEZ) to report final data from its 43-patient Phase 2 advanced ovarian cancer trial with its AEZS-108 drug, [...]

YM begins Phase 2 brain metastases trial for nimotuzumab

YM BioSciences (AMEX:YMI; TSX:YM) enrolled its first U.S. patient at the Florida Cancer Institute in a Phase 2 clinical trial evaluating its nimotuzumab drug in patients with brain metastases from NSCLC . Last year, the U.S. Department of the Treasury’s Office of Foreign Assets Control lifted the limitation on the development of nimotuzumab in the [...]

New data from YM’s nimotuzumab

YM BioSciences (TSX:YM; AMEX:YMI) of Mississauga and its European partner Oncoscience have reported additional data from a Phase 3 study of YM’s nimotuzumab drug in children with an inoperable form of brain cancer. “These results demonstrate that nimotuzumab continues its long record of differentiated and remarkable safety and that it brings important benefits to children [...]